Tests a magnesium supplement added to antidepressants for depression
Tests a magnesium supplement added to usual medicine in adults with depression.
Plain-language title generated from the registry record
Registry title: Magnesium Bisglycinate in Major Depressive Disorder
Key facts
- Where
- Bhubaneswar, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07633080, who can take part
Where in India
- All India Institute of Medical Sciences (AIIMS)Bhubaneswar, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- All India Institute of Medical Sciences, Bhubaneswar
- Trial code
- NCT07633080
- Record updated
- 15 June 2026
- Original description
Depression is a common illness that can affect a person's mood, sleep, energy, ability to work, and overall quality of life. While medicines are available to treat depression, many people do not get complete relief from their symptoms. This study will evaluate whether adding a magnesium supplement in the form of magnesium bisglycinate to regular antidepressant treatment can help improve symptoms of depression. Adults with depression who are already receiving treatment will be randomly assigned to receive either magnesium bisglycinate or a placebo (an inactive substance) along with their usual medication. The study will compare the two groups to see whether the supplement leads to greater improvement in symptoms, sleep, and day-to-day functioning. Information on any side effects will also be collected. The findings may help determine whether magnesium bisglycinate can be used as a safe and affordable additional treatment for people with depression.Read full original descriptionShow less
Efficacy and Safety of Add-on Magnesium Bisglycinate in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
Depression is a common illness that can affect a person's mood, sleep, energy, ability to work, and overall quality of life. While medicines are available to treat depression, many people do not get complete relief from their symptoms. This study will evaluate whether adding a magnesium supplement in the form of magnesium bisglycinate to regular antidepressant treatment can help improve symptoms of depression. Adults with depression who are already receiving treatment will be randomly assigned to receive either magnesium bisglycinate or a placebo (an inactive substance) along with their usual medication. The study will compare the two groups to see whether the supplement leads to greater improvement in symptoms, sleep, and day-to-day functioning. Information on any side effects will also be collected. The findings may help determine whether magnesium bisglycinate can be used as a safe and affordable additional treatment for people with depression.
Inclusion: Patients with a diagnosis of Major Depressive Disorder (MDD) as per DSM-5 criteria; Patients of either sex within the age group of 18-65 years; Mild to severe depression, defined as a baseline MADRS score ≥7; Currently receiving a stable dose of antidepressant monotherapy (SSRI or SNRI) in equivalent doses; Willing and able to provide written informed consent.
Exclusion: History of renal impairment (previous history of AKI, CKD, currently on dialysis); Electroconvulsive therapy (ECT) received within the past 3 months; Diagnosis of bipolar affective disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder; Current substance use disorder (except nicotine, alcohol and caffeine), as per DSM-5 criteria; History of significant severe medical comorbidity, including uncontrolled hypothyroidism, Cushing's syndrome, active malignancy, myasthenia gravis, or severe hepatic impairment; Known hypersensitivity or allergy to magnesium supplements or glycine; Concurrent use of magnesium-containing supplements, antacids, or laxatives; Use of medications with significant pharmacokinetic interactions with magnesium (e.g., tetracyclines, fluoroquinolones, bisphosphonates, diuretics) that cannot be temporally separated by ≥2 hours; Active suicidal ideation with intent or a recent suicide attempt (within the past 6 months), as assessed by the treating psychiatrist; Pregnancy, lactation, or women of childbearing potential not using adequate contraception.